Emergent BioSolutions Inc. (EBS) Investor Relations Documents

Emergent BioSolutions Inc. (EBS) investor relations documents from the company's IR site: 40 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-05Press releasePress release
2026-08-05Press releasePress release
2026-08-05Press releaseEmergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security En
2026-08-05Press releaseEmergent BioSolutions Reports Second Quarter 2026 Financial Results
2026-07-22Press releasePress release
2026-07-22Press releaseEmergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026
2026-06-29Press releasePress release
2026-06-29Press releaseEmergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mp
2026-06-04Press releasePress release
2026-06-04Press releaseEmergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opi
2026-05-28Press releasePress release
2026-05-28Press releaseEmergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D,
2026-05-20Press releasePress release
2026-05-20Press releaseEmergent BioSolutions to Participate in Upcoming Investor Conferences
2026-05-18Press releasePress release
2026-05-18Press releaseEmergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccin
2026-04-30Press releasePress release
2026-04-30Press releasePress release
2026-04-30Press releaseEmergent BioSolutions Reports First Quarter 2026 Financial Results
2026-04-30Press releaseEmergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (S
2026-04-29Press releasePress release
2026-04-29Press releasePress release
2026-04-29Press releaseEmergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diab
2026-04-29Press releaseEmergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spr
2026-04-28Press releasePress release
2026-04-28Press releaseEmergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encepha
Press releaseEmergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026
2026-04-16Press releasePress release
2026-04-16Press releasePress release
2026-04-16Press releaseEmergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexi
2026-04-09Press releasePress release
2026-04-09Press releaseEmergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Tak
2026-04-07Press releasePress release
2026-04-07Press releaseEmergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to
2026-04-02Press releasePress release
2026-04-02Press releaseEmergent BioSolutions Participates in Upcoming International Preparedness Conferences
2026-03-25Press releasePress release
2026-03-25Press releaseEmergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an Int
2026-03-03Press releasePress release
2026-03-03Press releaseEmergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors

EBS overview · EBS earnings · EBS financials · EBS KPIs · EBS ownership · EBS peers · EBS filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.